brand logo

Am Fam Physician. 2023;107(6):655-656

Author disclosure: No relevant financial relationships.

Guardant Health Shield blood testColorectal cancer screeningAverage-risk, asymptomatic adults 45 years and older who are not up to date with colorectal cancer screening$895

Guardant Health Shield is a proprietary blood test designed to identify genomic and epigenomic alterations in cell‐free DNA and proteomic changes in plasma for early detection of colon cancer.13 The test aims to detect methylation sequences in circulating tumor DNA (ctDNA) present in the bloodstream.1,2 Although not studied for screening, ctDNA has been studied to assess the benefit of adjuvant chemotherapy after colorectal cancer surgery.4 Other early‐detection blood tests for cancer are available, although none have been approved by the U.S. Food and Drug Administration (FDA).5 Shield is not a replacement for currently recommended colorectal cancer screening methods and does not have FDA approval.6

Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

This series is coordinated by Natasha Pyzocha, DO, contributing editor.

A collection of Diagnostic Tests published in AFP is available at

Continue Reading

More in AFP

More in Pubmed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.